Sodium-dependent glucose transporter protein as a potential therapeutic target for improving glycemic control in diabetes

被引:9
作者
Castaneda-Sceppa, Carmen [2 ]
Castaneda, Francisco [1 ]
机构
[1] Klin Herzberg, D-37412 Herzberg Am Harz, Germany
[2] Northeastern Univ, Bouve Coll Hlth Sci, Boston, MA 02115 USA
关键词
diabetes treatment; diabetes-related complications; hyperglycemia; sodium-glucose transport proteins; RANDOMIZED CONTROLLED-TRIAL; SELECTIVE SGLT2 INHIBITOR; SKELETAL-MUSCLE; INSULIN-RESISTANCE; VITAMIN-D; PHARMACOLOGICAL-PROPERTIES; COTRANSPORTER INHIBITORS; ANTIDIABETIC AGENTS; SIGNAL-TRANSDUCTION; PHYSICAL-ACTIVITY;
D O I
10.1111/j.1753-4887.2011.00423.x
中图分类号
R15 [营养卫生、食品卫生]; TS201 [基础科学];
学科分类号
100403 ;
摘要
Glucose is transported across the cell membrane by two different types of glucose transporters: glucose-facilitated transporters and sodium-dependent glucose transport (SGLT) proteins. Regulation of SGLT activity (namely, inhibition of SGLT1 and SGLT2 activity and stimulation of SGLT3 activity) represents a potential means of managing hyperglycemia and diabetes, thus preventing complications of diabetes. The purpose of the present review is to discuss the role of SGLT proteins in the pathophysiology of diabetes and to describe the mechanisms by which these transporters may be used for glycemic control and the treatment of diabetes. The regulatory processes involved in SGLT-mediated glucose uptake are also described briefly. This information provides new insight into the complementary mechanisms involved in the regulation of SGLT-mediated glucose transport as well as a basis for further investigation. (C) 2011 International Life Sciences Institute
引用
收藏
页码:720 / 729
页数:10
相关论文
共 127 条
[1]   Standards of Medical Care in Diabetes-2010 [J].
不详 .
DIABETES CARE, 2010, 33 :S11-S61
[2]   EXPRESSION OF THE MAJOR INSULIN-REGULATABLE GLUCOSE-TRANSPORTER (GLUT4) IN SKELETAL-MUSCLE OF NONINSULIN-DEPENDENT DIABETIC-PATIENTS AND HEALTHY-SUBJECTS BEFORE AND AFTER INSULIN INFUSION [J].
ANDERSEN, PH ;
LUND, S ;
VESTERGAARD, H ;
JUNKER, S ;
KAHN, BB ;
PEDERSEN, O .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1993, 77 (01) :27-32
[3]   Glycosidase inhibitors: update and perspectives on practical use [J].
Asano, N .
GLYCOBIOLOGY, 2003, 13 (10) :93R-104R
[4]   1,25-DIHYDROXYVITAMIN D-3-INDUCED UP-REGULATION OF THE THYROTROPIN-RELEASING-HORMONE RECEPTOR IN CLONAL RAT PITUITARY GH(3) CELLS [J].
ATLEY, LM ;
LEFROY, N ;
WARK, JD .
JOURNAL OF ENDOCRINOLOGY, 1995, 147 (03) :397-404
[5]  
Auwerx J, 1999, CELL, V97, P161
[6]   Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with metformin: a randomised, double-blind, placebo-controlled trial [J].
Bailey, Clifford J. ;
Gross, Jorge L. ;
Pieters, Anne ;
Bastien, Arnaud ;
List, James F. .
LANCET, 2010, 375 (9733) :2223-2233
[7]   Antiproliferative role of vitamin D and its analogs - a brief overview [J].
Banerjee, P ;
Chatterjee, M .
MOLECULAR AND CELLULAR BIOCHEMISTRY, 2003, 253 (1-2) :247-254
[8]  
Barclay A, 2010, AUST FAM PHYSICIAN, V39, P579
[9]   Dietary strategies for patients with type 2 diabetes in the era of multi-approaches; review and results from the Dietary Intervention Randomized Controlled Trial (DIRECT) [J].
Ben-Avraham, Sivan ;
Harman-Boehm, Ilana ;
Schwarzfuchs, Dan ;
Shai, Iris .
DIABETES RESEARCH AND CLINICAL PRACTICE, 2009, 86 :S41-S48
[10]  
Bloomgarden Zachary T, 2009, Diabetes Care, V32, pe64, DOI 10.2337/dc09-zb06